Endocrine and Metabolic Science最新文献

{"title":"Retrospective clinical analysis of time to recovery from diabetic ketoacidosis in Ethiopia","authors":"Angefa Ayele ,&nbsp;Dube Jara ,&nbsp;Alo Edin ,&nbsp;Digafe Hailu ,&nbsp;Mihiret Kifle ,&nbsp;Yohannes Fekadu","doi":"10.1016/j.endmts.2025.100224","DOIUrl":"10.1016/j.endmts.2025.100224","url":null,"abstract":"<div><h3>Background</h3><div>Diabetes is a metabolic disorder that affected &gt; or = 500 million people in 2021. Diabetic ketoacidosis is the most serious acute complication. Because of the significant health burden of diabetic ketoacidosis, we performed a retrospective study on the recovery time and predictors among adult diabetic mellitus patients in selected public hospitals in Southern Oromia in Ethiopia.</div></div><div><h3>Methods</h3><div>A retrospective follow-up study was conducted of 316 randomly selected adult diabetic ketoacidosis patients admitted between January 1, 2020, and July 31, 2023. A structured checklist was utilized. Data were entered into Epi-data version 4.6 and analyzed with STATA version 17, employing Kaplan-Meier survival curves, log-rank tests, and Cox-proportional hazards models to identify predictors. Results from bivariable and multivariable Cox-regression were reported via adjusted hazard ratio with 95 % confidence intervals.</div></div><div><h3>Results</h3><div>This study included 316 participants, with 256 adults (81.01 %) recovering throughout the follow-up period. The overall DKA recovery rate was 23.8 per 1000 person-hours (95 % CI: 22.21–27.07), and the median recovery time was 42 hr. Significant predictors of recovery time included random blood glucose level [AHR (95 % CI): 0.58 (0.38–0.90)], duration of diabetes mellitus [AHR (95 % CI): 0.24 (0.14–0.69)], and severity of DKA [AHR (95 % CI): 0.46 (0.16–0.84)].</div></div><div><h3>Conclusion</h3><div>The median DKA recovery time was prolonged, increasing the risk of complications. Blood glucose level, diabetes duration, and DKA severity were predictors of recovery time. Therefore, targeting these factors through research and interventions may improve outcomes and reduce DKA recovery duration.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100224"},"PeriodicalIF":0.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geospatial analysis and determinant factors of comorbidity presence in patients with diabetes in Peru","authors":"Víctor Juan Vera-Ponce ,&nbsp;Fiorella E. Zuzunaga-Montoya ,&nbsp;Luisa Erika Milagros Vásquez-Romero ,&nbsp;Joan A. Loayza-Castro ,&nbsp;Nataly Mayely Sanchez-Tamay ,&nbsp;Carmen Inés Gutierrez De Carrillo","doi":"10.1016/j.endmts.2025.100222","DOIUrl":"10.1016/j.endmts.2025.100222","url":null,"abstract":"<div><h3>Objective</h3><div>Given the significant increase in diabetes mellitus (DM) prevalence and its associated complications in recent decades, this study aimed to explore the determinant factors and geographical distribution of comorbidities and their number in patients with diabetes in Peru.</div></div><div><h3>Methods</h3><div>Cross-sectional study based on a database providing detailed demographic and clinical information on DM patients affiliated with the Seguro Integral de Salud (SIS) in Peru. The dependent variables in this study are twofold: the type of comorbidities present in DM patients and the number of comorbidities they have. Comorbidities were categorized into three groups: DM with obesity/dyslipidemia, DM with hypertension, and DM with mental health disorders. The number of comorbidities was classified as none, one, two, or three comorbidities.</div></div><div><h3>Results</h3><div>A total of 1,355,354 patients were included. Male patients, older individuals, and those with a longer time since diagnosis have different probabilities of presenting the comorbidities and a higher number of them. Additionally, the geospatial analysis showed apparent regional variations in the prevalence and number of comorbidities, highlighting the influence of environmental and socioeconomic factors and access to healthcare services.</div></div><div><h3>Conclusions</h3><div>This study identified significant demographic and clinical factors associated with comorbidities in patients with DM in Peru. These findings showed the need for personalized, region-specific diabetes management. Therefore, public health policies should adapt to meet the needs of different regions and groups. Improving healthcare access is crucial, especially where comorbidity prevalence is high. Further education programs must address diet and exercise comorbidities, focusing on vulnerable people.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100222"},"PeriodicalIF":0.0,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between metabolic syndrome and gallstone disease: A cross-sectional study from the PERSIAN Guilan cohort study","authors":"Hasti Zakeri Fardi ,&nbsp;Kourosh Mojtahedi ,&nbsp;Saman Maroufizadeh ,&nbsp;Farahnaz Joukar ,&nbsp;Fariborz Mansour-Ghanaei","doi":"10.1016/j.endmts.2025.100221","DOIUrl":"10.1016/j.endmts.2025.100221","url":null,"abstract":"<div><h3>Background</h3><div>There has been a concerning increase in the occurrence of gallstone diseases (GSDs) among individuals with metabolic syndrome (MetS). This study investigated the association between MetS and GSDs and related risk factors.</div></div><div><h3>Methods</h3><div>This retrospective cross-sectional study was conducted on 10,520 participants from the prospective epidemiological research studies of the Iranian adults (PERSIAN) Guilan cohort study (PGCS) population. Demographic and clinical characteristics, anthropometric parameters, and laboratory findings were collected. National Cholesterol Education Program–Adult Treatment Panel III criteria (NCEP-ATP III) were used to diagnose the MetS. All data was analyzed using SPSS version 26, and a significant level was considered &lt;0.05.</div></div><div><h3>Results</h3><div>The prevalence of MetS was 41.8 %, with higher rates in females (56.3 %) than males (25.0 %). Also, GSD prevalence was 2.06 %. Abdominal obesity and low high-density lipoprotein (HDL) levels were significantly associated with GSDs (<em>P</em> &lt; 0.05). The presence of MetS increased GSD odds by 47 % (<em>P=</em>0.010). A trend of increasing GSD prevalence with the number of MetS components illustrated a significant relationship ranging from 0.56 % (no components) to 3.60 % (all components) (<em>P</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>The findings demonstrated that MetS was significantly associated with increased risk of GSDs, of which higher body mass index (BMI), greater waist circumference, and lower HDL level were the most associated risk factors.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100221"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolomics identify serum biomarkers for predicting acute exacerbation and severity of bronchiectasis","authors":"Jiaxin Yan ,&nbsp;Fanxin Deng ,&nbsp;Xueli Wang ,&nbsp;Jing Wei ,&nbsp;Yang Cao ,&nbsp;Kaili Deng ,&nbsp;Xiaolin Chen ,&nbsp;Lei Shu ,&nbsp;Lei Shi ,&nbsp;Mingjing Wu ,&nbsp;Ganzhu Feng","doi":"10.1016/j.endmts.2025.100220","DOIUrl":"10.1016/j.endmts.2025.100220","url":null,"abstract":"<div><h3>Background</h3><div>Bronchiectasis (BE) is a chronic respiratory disease. Acute BE exacerbation caused by recurrent infections can lead to hemoptysis and even asphyxia, with high mortality and long hospitalization. This study aimed to identify novel diagnostic metabolic biomarkers for predicting acute exacerbation and severity of BE.</div></div><div><h3>Methods</h3><div>A liquid chromatography–mass spectrometry (LC–MS)-based untargeted metabolomic analysis was performed for serum samples from 45 patients with acute BE exacerbation and 15 healthy controls. The diagnostic value of the candidate metabolites was evaluated using receiver operating characteristic (ROC) curves.</div></div><div><h3>Results</h3><div>Based on bronchiectasis severity index (BSI) scores, patients with acute BE exacerbation were classified into mild, moderate, and severe BE groups. Compared to healthy controls, the abundance of 4-acetamidobutyric acid was elevated in the mild, moderate, and severe groups (<em>p</em> &lt; 0.05), with no significant difference among the three groups. In the severe BE group, the abundances of taurochenodecoxycholic acid, oleamide, hexadecanamide, and glycodeoxycholic acid were significantly elevated from those in mild and moderate BE groups (<em>p</em> &lt; 0.05), with Youden index (YI) ≥ 0.8 for all metabolites; the combination of these 4 metabolites had an area under the ROC curve (AUROC) of 0.99, a sensitivity of 100 % and a specificity of 93.3 % for identifying severe BE. Pathway analysis reveals that abnormally enriched metabolites in BE patients are associated with PI3K-Akt signaling pathway, mTOR signaling pathway, FoxO signaling pathway, renin-angiotensin system signaling pathway, asthma signaling pathway, and FcεRI signaling pathway, where prostaglandin D2 exerts direct or indirect impacts on these pathways.</div></div><div><h3>Conclusion</h3><div>4-Acetamidobutyric acid can serve as a biomarker for predicting acute BE exacerbation, while taurochenodecoxycholic acid, oleamide, hexadecanamide, and glycodeoxycholic acid are robust biomarkers for predicting severe BE. Prostaglandin D2 plays a crucial role in promoting the pathogenesis of pulmonary inflammatory cell recruitment, cell autophagy, and pulmonary fibrosis during acute BE exacerbation. Overall, this study identifies biomarkers for predicting acute BE exacerbation and provides new targets for drug development.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100220"},"PeriodicalIF":0.0,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma concentration of cyclic glycine proline is associated with impaired energy metabolism in a Chinese population of type 2 diabetes mellitus","authors":"Mengdi Zhu ,&nbsp;Fengxia Li ,&nbsp;Shuting Huang ,&nbsp;Li Huang ,&nbsp;Heng Zhang ,&nbsp;Lingyan Chen ,&nbsp;Vanessa Cave ,&nbsp;Jian Guan ,&nbsp;Yang Yang","doi":"10.1016/j.endmts.2025.100219","DOIUrl":"10.1016/j.endmts.2025.100219","url":null,"abstract":"<div><div>Insulin-like growth factor (IGF)-1 is an effector of cyclic glycine-proline (cGP) and regulates glucose metabolism and vascular remodeling. This study investigated the potential relationships of plasma concentrations of IGF-1, IGF binding protein-3 (IGFBP-3) and cyclic glycine-proline (cGP) to glucose intolerance and clinical vascular complications in a Chinese population of type - 2 diabetes mellitus (T2DM).</div><div>The study included the participants with T2DM only (<em>n</em> = 20), T2DM + hypertension (n = 20), T2DM + hypertension + diabetic peripheral neuropathy (DPN, <em>n</em> = 19) and 18 age-matched healthy controls. Fasting blood and spot urine samples were used for analysis.</div><div>Plasma concentration of cGP was positively associated with plasma concentrations of fasting glucose (<em>p</em> &lt; 0.001), triglyceride (p &lt; 0.001), HBAc-1 (%, p &lt; 0.001), triglyceride/glucose index (p &lt; 0.001), plasma concentrations of uric acid (<em>p</em> = 0.002), urine albumin (<em>p</em> = 0.008), and albumin/creatinine ratio (<em>p</em> = 0.019) in the T2DM only group. Plasma concentration of IGFBP-3 was positively associated with blood urea nitrogen in T2DM + hypertension group (p &lt; 0.001) and weakly associated foot DPN scores (<em>p</em> = 0.052) in the T2DM + hypertension + DPN group.</div><div>Elevated plasma cGP concentration that increases the amount of bioavailable IGF-1 was an adaptive response to glucose intolerance, hyperuricemia and albuminuria. Elevated plasma IGFBP-3 concentration that reduces the amount of bioavailable IGF-1, was associated with diabetic nephropathy and peripheral neuropathy. The changes of plasma concentration of cGP and IGFBP-3 may collectively assist in the prognosis of T2DM.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100219"},"PeriodicalIF":0.0,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of a novel weight-loss combination product containing orlistat and resveratrol on obesity: A multicenter randomized controlled study (EC-FIT)","authors":"Khin Maung Win ,&nbsp;Tint Swe Latt ,&nbsp;Aung Hlaing Bwa ,&nbsp;Khin Maung Aye ,&nbsp;Kyaw Soe Tun ,&nbsp;Hardik Gandhi","doi":"10.1016/j.endmts.2025.100218","DOIUrl":"10.1016/j.endmts.2025.100218","url":null,"abstract":"<div><h3>Background</h3><div>Orlistat, a weight loss medication, is often less effective due to poor adherence to the dietary and exercise recommendations. However, its effectiveness is often compromised by poor adherence to recommended lifestyle changes and side effects like steatorrhea. Combining orlistat with resveratrol may enhance weight loss and offer additional metabolic benefits.</div></div><div><h3>Objective</h3><div>This study evaluated the real-world efficacy and safety of orlistat combined with resveratrol versus orlistat alone in overweight or obese individuals in Myanmar.</div></div><div><h3>Method</h3><div>Obese adults (BMI ≥ 25 kg/m²) were randomized into two groups for a 12-week study. The Orlistat (O) group received orlistat 120 mg three times daily, while the Orlistat &amp; Resveratrol (O-R) group took orlistat 120 mg plus resveratrol 100 mg thrice daily. Primary outcome measured was weight change; secondary outcomes included Total Cholesterol, LDL-cholesterol, Blood pressure, HbA1c, alanine transaminase (ALT), controlled attenuation parameter (CAP), Liver stiffness, and Total Body Fat. Adverse events were also recorded.</div></div><div><h3>Result</h3><div>The O-R group lost more weight (−3.31 kg, 95 % CI: 2.36–5.04, <em>p</em> &lt; 0.001) than the O group (−2.92 kg, 95 % CI: −2.6442–4.5471, <em>p</em> &lt; 0.001). Additionally, the O-R group showed greater reductions in total body fat (−4.93 %), diastolic blood pressure (78.38 mmHg vs 75.93 mmHg; 95 % CI: 0.4473–4.4707, <em>p</em> &lt; 0.05), and CAP score (276.62 dB/m vs 253.16 dB/m; 95 % CI: 8.46–38.85, <em>p</em> &lt; 0.05). Significant weight loss in the O-R group was observed in obese patients with steatosis (S1–S3) or fibrosis (F2–F4), and in diabetic patients, particularly those with a BMI ≥30 (−2.79 kg vs −1.04 kg, <em>p</em> &lt; 0.05) and steatosis (−2.17 kg vs −0.44 kg, <em>p</em> &lt; 0.05). Steatorrhea occurred in both groups, while diarrhoea was noted only in the O group.</div></div><div><h3>Conclusion</h3><div>Addition of resveratrol to orlistat provides synergistic benefits to weight loss with additional benefit in terms of reducing total body fat and diastolic BP. These benefits were also apparent in subgroup of patients with diabetes suffering from obesity or steatosis.</div><div>Trial registration number: ISRCTN10642495.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100218"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleeve gastrectomy and pancreatic omentoplasty decrease insulin resistance: Impact on pro-inflammatory and anti-inflammatory cytokine gene expression","authors":"Abdul Mughni ,&nbsp;Reno Rudiman ,&nbsp;Tjokorda Gde Dalem Pemayun ,&nbsp;Bella Renata ,&nbsp;Endang Mahati ,&nbsp;Suharyo Hadisaputro ,&nbsp;Ignatius Riwanto","doi":"10.1016/j.endmts.2025.100217","DOIUrl":"10.1016/j.endmts.2025.100217","url":null,"abstract":"<div><h3>Background</h3><div>Chronic systemic inflammation in obesity impairs insulin sensitivity and contributes to insulin resistance. Laparoscopic sleeve gastrectomy results in substantial weight loss and improved diabetic status, although 25 % of patients do not achieve optimal insulin production due to pancreatic fat accumulation. Addressing pancreatic inflammation is essential for better glycemic control. Pancreatic omentoplasty may enhance vascularization and reduce inflammation. This study examines the effects of sleeve gastrectomy and pancreatic omentoplasty on insulin resistance by analyzing the gene expression of pro- and anti-inflammatory cytokines and their correlation with HOMA-IR values.</div></div><div><h3>Method</h3><div>An experimental study with post-test only control design was conducted with obese and type 2 diabetes mellitus (T2DM) rat subjects which underwent sleeve gastrectomy treatment (SG), a combination of pancreatic omentoplasty and sleeve gastrectomy (SG + PO), without any intervention or a positive control group (+control), and rats which were neither obese nor T2DM or a negative control group (−control). On day 10 after surgery, blood samples from the rats were taken to assess blood glucose and insulin level in order to calculate HOMA-IR. Then, the pancreatic tissue of each rats was taken to extract the mRNA of TNF-α, IL-1, IL-6, and IL-10 by reverse-transcription polymerase chain reaction.</div></div><div><h3>Result</h3><div>The expression of the pro-inflammatory cytokine TNF-α in the SG + PO group was lower compared to the SG group (<em>p</em> = 0.008), IL-1 in the SG + PO group was lower than in the SG group (<em>p</em> = 0.043), and IL-6 in the SG + PO group was lower compared to the control group (<em>p</em> = 0.001). In contrast, the anti-inflammatory cytokine IL-10 was higher in the SG + PO group compared to the SG group (<em>p</em> = 0.001). Additionally, HOMA-IR in the SG + PO group was lower compared to the SG group (p = 0.001).</div></div><div><h3>Conclusion</h3><div>The combination of sleeve gastrectomy and pancreatic omentoplasty reduces pro-inflammatory cytokints (TNF-α, IL-1, IL-6) and increases anti-inflammatory cytokine IL-10, compared to sleeve gastrectomy alone. It also significantly lowers insulin resistance (HOMA-IR), suggesting that the combined procedure improves insulin sensitivity and glycemic control, cytokine modulation.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100217"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between abdominal obesity and hyperuricaemia in individuals with type 2 diabetes mellitus: A case–control study","authors":"Ruihao Liu ,&nbsp;Yuanyuan Zhang ,&nbsp;Zhiming Hu ,&nbsp;Huijian Deng","doi":"10.1016/j.endmts.2025.100216","DOIUrl":"10.1016/j.endmts.2025.100216","url":null,"abstract":"<div><h3>Background</h3><div>Obesity is associated with hyperuricaemia in the general population; however, that relationship has not been studied in detail in patients with type 2 diabetes mellitus (T2DM), nor has the possibility of sex differences in that relationship been investigated.</div></div><div><h3>Methods</h3><div>A retrospective case–control study was conducted. We explored the correlation between abdominal obesity and hyperuricaemia among 315 Chinese patients with T2DM aged 27–64 years who had received community health services between January 2021 and August 2022. Abdominal obesity was defined as a waist circumference ≥ 85.0 cm in females and ≥ 90.0 cm in males. Hyperuricaemia was defined as a serum uric acid level &gt; 7.0 mg/dL in males and postmenopausal females, &gt; 6.0 mg/dL in premenopausal females, or receiving medical treatment for hyperuricaemia. The male and female groups were each separately divided into two additional groups: those with abdominal obesity and those without abdominal obesity. Odds ratios (OR) and 95 % confidence intervals (CI) for the risk of hyperuricaemia were calculated using a logistic regression model.</div></div><div><h3>Results</h3><div>The prevalence of hyperuricaemia in male and female patients in the study area was 42.86 % and 28.00 %, respectively. Abdominal obesity (<em>OR</em> = 3.369, <em>95</em> <em>% CI</em> = 1.031–11.009, <em>P</em> value &lt;0.05) was the determinant variable for hyperuricaemia among male patients with T2DM but not among female patients. There was no significant difference in the prevalence of hyperuricaemia between male or female T2DM patients with different body mass index (BMI) levels.</div></div><div><h3>Conclusions</h3><div>Our study revealed that abdominal obesity, but not overall obesity, was associated with an increased risk of hyperuricaemia in male patients with T2DM. Neither abdominal obesity nor overall obesity was associated with an increased risk of hyperuricaemia in female patients with T2DM. Abdominal obesity is a more effective predictor of hyperuricaemia than overall obesity is in male patients with T2DM.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100216"},"PeriodicalIF":0.0,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer, deuterium, and gut microbes: A novel perspective","authors":"Stephanie Seneff ,&nbsp;Anthony M. Kyriakopoulos","doi":"10.1016/j.endmts.2025.100215","DOIUrl":"10.1016/j.endmts.2025.100215","url":null,"abstract":"<div><div>Deuterium is a natural isotope of hydrogen, containing a neutron as well as a proton, which makes it twice as heavy as hydrogen. In this paper, we develop a theoretical argument that human metabolism strives to minimize the amount of deuterium in mitochondrial water, because it causes a stutter in ATPase pumps, introducing excess reactive oxygen species and reduced ATP production. Gut microbes produce hydrogen gas that is 80 % depleted in deuterium (deupleted). This gas is recycled into organic matter that supplies deupleted nutrients to the host, such as acetate, butyrate, and choline. Mitochondrial dysfunction is associated with many chronic diseases, most notably, cancer. Dehydrogenases, through proton tunneling, typically have a high deuterium kinetic isotope effect (KIE), and they supply deupleted protons to the ATPase pumps via NADH (nicotinamide adenine dinucleotide) synthesis. We propose that a tumor may arise as a consequence of mitochondrial stress in immune cells due to excess deuterium, and that the tumor microenvironment can support immune cell recovery from mitochondrial dysfunction. Cancer cells alter protein expression to support deuterium sequestration through membrane-bound vesicular ATPase, and they release deupleted nutrients, mainly lactate, into the extracellular milieu and the circulation. Deuterium depleted water (DDW) has been shown to prolong life in cancer patients. An organic high fat diet rich in B vitamins, especially niacin, riboflavin, and folate, augmented with natural prebiotics and probiotics, supports deuterium homeostasis and likely protects from cancer.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100215"},"PeriodicalIF":0.0,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sirtuin, irisin, and vitamin D as predictors of diabetes mellitus with uncontrolled glycemia in Indonesian patients","authors":"Elly Herwana ,&nbsp;Yenny ,&nbsp;Alvina ,&nbsp;Kurniasari ,&nbsp;Clarissa Asha Febinia ,&nbsp;Pusparini","doi":"10.1016/j.endmts.2024.100214","DOIUrl":"10.1016/j.endmts.2024.100214","url":null,"abstract":"<div><div>The incidence of type 2 diabetes mellitus is increasing in developing countries, including Indonesia. Insulin resistance is a significant contributor to elevated blood glucose levels in type-2 diabetes patients. Low levels of serum sirtuin-1, irisin, and vitamin D have been linked to insulin resistance. This study aimed to identify risk factors that could predict uncontrolled glycemia and insulin resistance in Indonesian type-2 diabetes patients. We conducted a cross-sectional study with 73 adults from South Jakarta, Indonesia, in which we examined type-2 diabetes risk factors and biomarkers, including sex, age, body mass index, waist circumference, waist–to–hip ratio, fasting blood glucose (FBG) levels, fasting insulin, sirtuin-1, irisin, and vitamin D levels. The subjects were categorized into two groups based on their glycated hemoglobin (HbA1c) level and homeostatic model assessment for insulin resistance (HOMA-IR) index to assess glycemic control and insulin resistance, respectively. We compared risk factor profiles between groups and analyzed multivariate relationships with logistic regression. Our findings revealed that 54 % of the subjects had uncontrolled glycemia, whereas only 11 % had insulin resistance. There was a significant association between uncontrolled glycemia and reduced sirtuin-1 levels (odds ratio = 4.07; <em>p</em> = 0.03), which was confirmed in the multivariate analysis (beta = 5.41, <em>p</em> = 0.014) along with FBG (beta = 36.88, <em>p</em> = 0.001). Irisin showed a marginal association with insulin resistance in both univariate (odds ratio = 0.12; <em>p</em> = 0.027) and multivariate analyses (beta = 0.09; <em>p</em> = 0.049). In conclusion, sirtuin-1, in addition to FBG, is a potential marker for assessing glycemic control in type-2 diabetes patients.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100214"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}